title: Effect of prostaglandin E-1 on Wisconsin University and histidine-tryptophan-ketoglutarate preservation solutions on preservation injury of the perfused liver.
abstract: BACKGROUND
  The aim of this study was to investigate the effects of prostaglandin E-1 (PGE-1) on preservation injury in livers perfused with the University of Wisconsin (UW) or histidine-tryptophan-ketoglutarate (HTK) solutions.
  
  
  METHODS
  Five groups each including six rats included. Ringer's lactate RL (group 1), HTK (group 2), HTK + PGE-1 (group 3), UW (group 4), or UW PGE-1 (group 5). Liver tissue and preservation fluid samples were obtained from the perfused lives for pathological and biochemical examinations respectively at 0, 6 and 12 hours.
  
  
  RESULTS
  Upon biochemical examination, aspartate aminotrasnferase and alanine aminotransferase values were highest among the group with RL solution and lowest with PGE-1. Liver structure was found to be damaged immediately after RL solution, whereas it was preserved in the other four groups. Fewer cellular changes were reported at the end of 12 hours in the groups administered PGE-1 compared with the other groups.
  
  
  CONCLUSIONS
  PGE-1 when applied before preservation protected liver functions, decreased pathologic injury, and delayed changes that occur under cold ischemic conditions.
authors.affiliation: Department of General Surgery, Dicle University Faculty of Medicine, Diyarbakir, Turkey. ialiosman@gmail.com
authors.forename: I
authors.initials: I
authors.lastname: Aliosmanoglu
authors.forename: S
authors.initials: S
authors.lastname: Sevmis
authors.forename: H
authors.initials: H
authors.lastname: Karakayali
authors.forename: A
authors.initials: A
authors.lastname: Kocbiyik
authors.forename: A
authors.initials: A
authors.lastname: Dagdeviren
authors.forename: A
authors.initials: A
authors.lastname: Haberal
authors.forename: M
authors.initials: M
authors.lastname: Haberal
mesh_terms: D000241:Adenosine / Q000494:pharmacology; D000410:Alanine Transaminase / Q000378:metabolism; D000493:Allopurinol / Q000494:pharmacology; D000527:Alprostadil / Q000494:pharmacology*; D000818:Animals; D001219:Aspartate Aminotransferases / Q000378:metabolism; D015415:Biomarkers / Q000378:metabolism; D050377:Cold Ischemia / Q000009:adverse effects*; D019610:Cytoprotection; D005947:Glucose / Q000494:pharmacology; D005978:Glutathione / Q000494:pharmacology; D006498:Hepatectomy; D007328:Insulin / Q000494:pharmacology; D007552:Isotonic Solutions / Q000494:pharmacology; D008099:Liver / Q000098:blood supply / Q000187:drug effects* / Q000201:enzymology / Q000473:pathology; D008297:Male; D008353:Mannitol / Q000494:pharmacology; D009926:Organ Preservation / Q000379:methods*; D019188:Organ Preservation Solutions / Q000494:pharmacology*; D010477:Perfusion; D011189:Potassium Chloride / Q000494:pharmacology; D011343:Procaine / Q000494:pharmacology; D011887:Raffinose / Q000494:pharmacology; D051381:Rats; D017208:Rats, Wistar; D015427:Reperfusion Injury / Q000209:etiology / Q000378:metabolism / Q000473:pathology / Q000517:prevention & control*; D000077325:Ringer's Lactate; D013997:Time Factors
chemical_list: D015415:Biomarkers; C039984:Bretschneider cardioplegic solution; D007328:Insulin; D007552:Isotonic Solutions; D019188:Organ Preservation Solutions; D000077325:Ringer's Lactate; C055206:University of Wisconsin-lactobionate solution; D008353:Mannitol; D011343:Procaine; D000493:Allopurinol; D011189:Potassium Chloride; D001219:Aspartate Aminotransferases; D000410:Alanine Transaminase; D000527:Alprostadil; D005978:Glutathione; D005947:Glucose; D000241:Adenosine; D011887:Raffinose